Depakene and Cortril drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Depakene and Cortril. Common interactions include anaemia among females and anti-insulin antibody positive among males.

The phase IV clinical study analyzes what interactions people who take Depakene and Cortril have. It is created by eHealthMe based on reports of 42 people who take Depakene and Cortril from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Nov, 26, 2022

42 people who take Depakene and Cortril together, and have interactions are studied.


What is Depakene?

Depakene has active ingredients of valproic acid. It is often used in epilepsy. eHealthMe is studying from 14,610 Depakene users for its effectiveness, alternative drugs and more.

What is Cortril?

Cortril has active ingredients of hydrocortisone. eHealthMe is studying from 1,456 Cortril users for its effectiveness, alternative drugs and more.

Number of Depakene and Cortril reports submitted per year:

Depakene and Cortril drug interactions.

Common Depakene and Cortril drug interactions by gender *:

female:

  1. Anaemia
  2. Platelet count decreased
  3. Disease progression
  4. Meningioma malignant
  5. Neutrophil count decreased
  6. White blood cell count decreased
  7. Altered state of consciousness
  8. Cerebral atrophy
  9. Germ cell cancer
  10. Hypoalbuminaemia

male:

  1. Anti-insulin antibody positive
  2. Diabetes mellitus inadequate control
  3. Respiratory depression
  4. Somnolence
  5. Status epilepticus
  6. Temporal lobe epilepsy
  7. Vomiting
  8. Craniopharyngioma
  9. Disease recurrence
  10. Facial pain

Common Depakene and Cortril drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Neoplasm recurrence
  2. Germ cell cancer
  3. Loss of consciousness
  4. Pyrexia
  5. Respiratory depression
  6. Somnolence
  7. Status epilepticus
  8. Vomiting
  9. Brain neoplasm
  10. Craniopharyngioma

20-29:

  1. Anti-insulin antibody positive
  2. Diabetes mellitus inadequate control
  3. Diabetic ketoacidosis
  4. Blood cortisol decreased
  5. Drug ineffective
  6. Hyponatraemia
  7. Blood glucose increased
  8. Brain stem stroke
  9. Cholecystitis infective
  10. Coma

30-39:

  1. Disease progression
  2. Hydrocephalus
  3. Hypothyroidism
  4. Inflammation
  5. Meningioma malignant
  6. Neutrophil count decreased
  7. Osteomyelitis
  8. Platelet count decreased
  9. Radiation injury
  10. Septic shock

40-49:

n/a

50-59:

  1. Fall
  2. Somnolence
  3. Adrenal insufficiency
  4. Altered state of consciousness
  5. Asthenia
  6. Brain stem haemorrhage
  7. Panic disorder
  8. Temporal lobe epilepsy
  9. Disease recurrence
  10. Dizziness

60+:

  1. Anaemia
  2. Cerebral atrophy
  3. Device related infection
  4. Disease progression
  5. Gamma-glutamyltransferase increased
  6. Hypophagia
  7. Hypotension
  8. Lymphocyte count decreased
  9. Nausea
  10. Neutrophil count decreased

Common conditions people have *:

  1. Diabetes: 8 people, 19.05%
  2. Hypopituitarism (diminished hormone secretion by the pituitary gland, causing dwarfism in children and premature aging in adults): 7 people, 16.67%
  3. Anaplastic Astrocytoma (tumour of the glial (supportive) tissue of the brain): 7 people, 16.67%
  4. Growth Hormone Deficiency: 5 people, 11.90%
  5. Type 2 Diabetes: 4 people, 9.52%
  6. Constipation: 4 people, 9.52%
  7. Adrenal Insufficiency (condition in which the adrenal glands do not produce adequate amounts of steroids): 4 people, 9.52%
  8. Pituitary Tumor Benign: 3 people, 7.14%
  9. Pain: 3 people, 7.14%
  10. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Depakene and Cortril?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Depakene and Cortril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Depakene side effects:

Browse all side effects of Depakene:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Cortril side effects:

Browse all side effects of Cortril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Depakene interactions:

Browse all interactions between Depakene and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Cortril interactions:

Browse all interactions between Cortril and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on valproic acid and hydrocortisone (the active ingredients of Depakene and Cortril, respectively), and Depakene and Cortril (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Depakene and Cortril.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: